Harrow, Inc. (NASDAQ:HROW) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund trimmed its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 36.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 13,901 shares of the company’s stock after selling 8,126 shares during the period. New York State Common Retirement Fund’s holdings in Harrow were worth $466,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Harrow by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after buying an additional 227 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in Harrow during the 3rd quarter worth $329,000. Corrado Advisors LLC purchased a new stake in Harrow in the third quarter valued at $331,000. Oppenheimer & Co. Inc. acquired a new position in Harrow in the third quarter valued at $1,267,000. Finally, Huntington National Bank purchased a new position in shares of Harrow during the third quarter worth about $164,000. 72.76% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HROW has been the subject of several research reports. HC Wainwright assumed coverage on Harrow in a report on Thursday, February 6th. They issued a “buy” rating and a $57.00 target price for the company. B. Riley cut their price target on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th.

Harrow Trading Up 1.9 %

NASDAQ HROW opened at $26.11 on Wednesday. The firm’s fifty day moving average is $32.20 and its two-hundred day moving average is $39.84. Harrow, Inc. has a one year low of $9.30 and a one year high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm has a market cap of $929.91 million, a PE ratio of -27.78 and a beta of 0.69.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.